Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Alternative Payment Models
- Biopharmaceutical Innovation
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Utilization Management & Step Therapy
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Audience
Display Only
Showing 121 Results
NPC Submits Comments Regarding the Medicare Hospital Outpatient Prospective Payment System
NPC submitted comments to CMS regarding the Medicare Hospital Outpatient Prospective Payment System (OPPS) Proposed Rule for Calendar Year 2025.
NPC Submits Comments to CMS on Proposed Rule on CY 2025 Payment Policies and More
In response to CMS' request for comments, NPC shared its input on the proposed rule for payment policies under the Medicare Physician Fee Schedule for calendar year 2025.
NPC responds to CMS's Information Collection Request on the Negotiation Data Elements and Drug Price Negotiation Process for the Initial Price Applicability Year 2027
NPC offered the agency insights on the data collection requirements it has proposed to inform the second round of the the price-setting efforts in the Medicare Drug Price Negotiation Program.
NPC Submits Comments on Next Steps in the 21st Century Cures Initiative
NPC's comments respond to a Congressional Request for Information soliciting input on opportunities to build on the 21st Century Cures Act.
NPC Submits Comments to CMS on Draft Guidance for the Medicare Drug Price Negotiation Program for 2027
In this comment letter, NPC weighs in on CMS' s draft guidance regarding the second cycle of the Medicare Drug Price Negotiation Program.
NPC Comments Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights
NPC submitted comments to the National Institute of Standards and Technology in response to the Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise…
NPC Comments on HHS Notice of Benefit and Payment Parameters for 2025
In this comment letter, NPC offers input on HHS' Notice of Benefit and Payment Parameters for 2025, annual rulemaking that governs programs and health plans offered under the Affordable Care Act.
NPC Submits Comments to CMS on Proposed Changes to Medicare Programs
In this comment letter, NPC weighs in on CMS' proposed technical and policy changes to Medicare Advantage and other Medicare programs.
NPC Submits Comments to CMS on Medicaid Drug Rebate Program
In this comment letter, NPC weighs in on CMS' proposed rule changes to the Medicaid Drug Rebate Program (MDRP).
NPC Comments on Proposed Changes for ICER Value Assessment Framework
NPC's comments highlight key concerns related to proposed changes to ICER's 2023 Value Assessment Framework.
NPC Comments on CMS' Drug Price Negotiation Counteroffer Information Collection Request
As CMS develops the detailed steps involved in the agency's drug pricing processes, NPC's comments highlight key shortcomings in the agency's counteroffer information collection request (ICR).
NPC Comments on CMS Information Collection Request for Negotiation Data Elements
NPC's comments offer input on the agency's latest efforts to implement the drug price-setting provisions of the Inflation Reduction Act through the design of a data collection process.
NPC Comments on CMS Medicare Drug Price Negotiation Program
NPC's comments highlight concerns about the agency's guidance regarding the implementation of Medicare Drug Price Negotiation and the potential for unintended consequences, including less…
NPC Comments on CMS's Hospital Outpatient Prospective Payment Systems Proposed Rule
NPC comments raise potential concerns as CMS states its intent to make significant changes to the payment rate for drugs purchased through the 340B program.
NPC Comments on CMS CY 2023 Payment Policies under the Physician Fee Schedule
NPC's comments offer input on CMS's implementation of the Discarded Drug Refund Policy, support continuing the add-on payment for at-home COVID-19 vaccinations, and provide recommendations on the…
NPC Comments on CMS Request for Information on the Medicare Program
NPC's comments to CMS's recent request for information on the Medicare program focus on access, innovation and the importance of patient engagement.
NPC Comments on the Medicare Program's Hospital Inpatient Prospective Payment Systems
NPC's comments to CMS focus on recent proposals related to the transition to National Drug Codes for New Technology Add-on Payments and recommendations regarding payment mechanisms to improve access…
Comments to FTC on Business Practices of PBMs and Their Impact on Pharmacies and Consumers
NPC submitted comments to the Federal Trade Commission encouraging the study of anti-competitive business practices of pharmacy benefit managers and their impact on drug affordability and access.
NPC Comments on HHS Notice of Benefit and Payment Parameters for 2023
NPC offers research-based comments to improve patient access to care and health equity.
NPC Comments on CMS' Proposed Medicare Shared Savings and Physician Fee Policies
NPC offers research-based comments to improve CMS' Merit-based Incentive Payment System Value Pathways and quality measurement.